A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis

Yee, Richard W.; Tepedino, Michael; Bernstein, Paula; Jensen, Harold G.; Schiffman, Rhett M.; Whitcup, Scott M.; Bid, Gatifloxacin

doi:10.1185/030079905x30699

Cited by 29 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Fluoroquinolones are concentrationdependent antibacterial agents 23 ; therefore, increasing the concentration of gatifloxacin may improve efficacy. In addition, enhancing the antibacterial activity of gatifloxacin 0.3% also may help prevent selection of resistant mutants.…”

Section: Introductionmentioning

confidence: 99%

Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older

HellerWarren

CruzMarilou²,

Rusi

et al. 2014

Journal of Ocular Pharmacology and Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older

HellerWarren

CruzMarilou²,

Rusi

et al. 2014

Journal of Ocular Pharmacology and Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…13,14 Studies have shown that topical gatifloxacin solution may be effective in prevention of infectious conditions such as conjunctivitis, keratitis, and postcataract endophthalmitis. 15,16 Owing to the benefits offered by gatifloxacin, various manufacturers have introduced gatifloxacin eyedrops (0.3% wt/vol). Fluoroquinolones have pHdependent solubility.…”

Section: Introductionmentioning

confidence: 99%

Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops

Majumdar

2006

AAPS PharmSciTech

View full text Add to dashboard Cite

The purpose of this research was to optimize the formulation factors for maximum in vitro permeation of gatifloxacin from aqueous drops through excised goat cornea and to evaluate the permeation characteristics of drug from selected marketed eyedrop formulations. Permeation studies were conducted by putting 1 mL of formulation on the cornea (0.67 cm 2 ) fixed between the donor and receptor compartments of an all-glass modified Franz diffusion cell and measuring gatifloxacin concentration in the receptor (containing normal saline under stirring) by spectrophotometry at 291.5 nm, after 120 minutes. Raising the drug concentration of the drops increased the drug permeation but decreased the percent permeation and the in vitro ocular availability. Raising the pH of the formulation from pH 5 to 7.2 increased both the drug permeation and the in vitro ocular availability. Eyedrops containing benzalkonium chloride (BAK; 0.01% wt/vol) and disodium edetate (EDTA; 0.01% wt/vol) showed maximum permeation, followed by Zymar, BAK (0.01% wt/vol), Gatilox, Gatiquin, and Gate (statistically significant P G .05 compared with control). In vitro titration of the formulations with 0.1N NaOH indicated the presence of a buffer in Zymar (pH 6) and Gate (pH 5.8), which may cause irritation and induce lacrimation, resulting in reduced ocular availability in vivo. Thus, formulation with BAK and EDTA, which is unbuffered, has a better likelihood of being absorbed in vivo. The BAK-EDTA formulation significantly (P G .05) increased the permeation of gatifloxacin through paired excised corneas of goat, sheep, and buffalo, compared with the control formulation. The goat cornea showed the greatest increase in permeation, followed by the sheep and buffalo corneas.

show abstract

“…Two cases out of twelve who were administered Tobramycin and one out of six administered Ofloxacin were using the drug twice a day instead of the standard regimen of six hourly administration 13 . One person was incorrectly administered Gatifloxacin three times a day against the standard regimen of six hourly dosing 14 .…”

Section: Discussionmentioning

confidence: 99%

Role of Antimicrobials in Intra Ocular Lens (Iol) Implantation

Banderao¹,

Binjawadgi²,

Dass³

2013

jemds

View full text Add to dashboard Cite

-CONTEXT: Pharmacotherapy which means use of drugs for prevention and treatment of diseases is a major branch of therapeutics. Cataract, particularly in the age group of 40-75 years is fairly common.Many potent drugs like Glucocorticoids, Antimicrobials etc. are used in the management of cataract. Antimicrobials use has led to a big concern amongst clinicians as many consider it to be unnecessary, inappropriate and downright dangerous.Recently increased attention has been diverted to rational prescribing and drug utilisation studies play a major role in this regard. These studies not only detect flaws in the therapy, but also help to find out solution to rectify the same.Anti-microbials are prescribed for almost all cases posted for Intra Ocular Lens Implantation Surgery. Hence the present prospective observational study was undertaken with respect to the use of anti-microbials (both prophylactic and post-operative) in Ophthalmology practice. Page 4853 RESULTS AND CONCLUSION: Our study found that Moxifloxacin is the most frequently prescribed anti-microbial pre-operatively for IOL implantation. Also, Moxifloxacin is the most frequently prescribed anti-microbial post-operatively for IOL implantation.Overall Moxifloxacin is currently the most frequently prescribed anti-microbial for both pre and post-operative use in IOL implantation surgery.

show abstract

A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis

Abstract: In this study, gatifloxacin 0.3% administered BID was as effective and as safe as gatifloxacin 0.3% administered QID for 5 days for the treatment of bacterial conjunctivitis.

Cited by 29 publications

References 4 publications

Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older

Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older

Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops

Role of Antimicrobials in Intra Ocular Lens (Iol) Implantation

Contact Info

Product

Resources

About